BioOhio BioBulletin, October 2014

Posted by BioOhio on Oct. 30, 2014

BioBulletin

Welcome to the October BioBulletin,

Trivia this month, in the spirit of Halloween: Wesley Earl “Wes” Craven, the American film director, writer, producer, and actor known for his work on horror/slasher films, is from where? Cleveland, Ohio! Furthermore, Craven’s film, A Nightmare on Elm Street, was set in fictional Springwood, Ohio. The actual house and filming took place at a private home located in Los Angeles.

Now to the “creepy” world of bioscience…


BioOhio Annual Conference Road Show

Join us Nov. 12 in Columbus for the powerful finale of three annual conferences we’ve hosted this fall.

Highlights include panels on Additive Manufacturing/3D Printing; Transforming Healthcare via Healthcare IT; Ohio Clinical Trials Collaborative; Integrating Veterinary Applications to accelerate your pharma/device company; Success Stories; and much more.

The networking reception will feature live music from bioscience community friends!

Click here for event details, including agenda, registration ($195 for members/$345 for non-members), location and more

(more…)

BioOhio remembers Frank Samuel, President of VentureOhio

Posted by BioOhio on Oct. 21, 2014

Frank Samuel PICAll of us at BioOhio are saddened to share the news that Frank Samuel, President of VentureOhio, was killed yesterday afternoon in a single car accident in Northeast Ohio. Frank was one of Ohio’s most vibrant leaders, including serving as BioOhio’s second President.

Update:  The Samuel family has announced that a public memorial service will be held for Frank on Sunday, November 2nd, 2:00pm at the Kent State University – Geauga campus, 14111 Claridon Troy Road, Burton, Ohio. For those wishing to send cards of condolence, they can be mailed to Jacqueline Samuel at 14219 Claridon Troy Road, P.O. Box 283, Burton, OH  44021.

“Frank was a good man and a good friend to many, and he will be sorely missed,” said John Rice, Managing Partner at Triathlon Medical Ventures & BioOhio Board Member, “Please keep him, his wife Jacqueline and his family in your thoughts and prayers.”

BioOhio was fortunate to have Frank join us just weeks ago as a speaker at our Annual Conference in Cincinnati. He spoke with great passion about his newest endeavor, VentureOhio. Frank highlighted the need to build infrastructure around the investment community to support entrepreneurial efforts in Ohio.

“I am often asked, why create VentureOhio? Because the time had come. We need three things to succeed; capital managed in Ohio, from early stage through maturity; a robust ecosystem to support entrepreneurship; and effective storytelling about all the successes that happen in Ohio.”

A message from John McIlwraith, VentureOhio Chairman has been posted on the organization’s website, you can read it here, and we’ve copied the full message below. More information in the media is available from these sources:  Geauga County Maple Leaf, Crain’s Cleveland Business, WKYC3.

National advocacy group AdvaMed issued this tribute (pdf) in an upcoming issue of the Gray Sheet.

Our thoughts and sympathies go out to his family and everyone that knew him.


Frank Samuel was President of VentureOhio, Inc. an organization founded in 2013 to advance entrepreneurial business growth in Ohio. Prior to this position, he was founding President of the Geauga Growth Partnership, Inc., a business-led economic development organization in Geauga County (Northeast Ohio). He was Science and Technology Advisor to the Governor of Ohio from 2000 – 2007, when he was a principal architect of Ohio’s Third Frontier program. Frank worked to advance Ohio’s bioscience community as BioOhio’s second President. Samuel served on the National Advisory Council of the California Health Benefits Review Program and the Board of Directors of the Global Cardiology Innovation Center of the Cleveland Clinic. He served as Chair and Board member for Providence Hospital (Washington, D.C.), a member of Institute of Medicine advisory bodies on biomedical technology issues, a member of several biomedical company boards of directors, and President of the Health Industry Manufacturers Association (now AdvaMed).  A graduate of Hiram College and Harvard Law School, his paper recommending a venture capital strategy for the Great Lakes region was published in 2010 by The Brookings Institution (Washington, D.C.).


 

VentureOhio-312To VentureOhio Members and the Entrepreneurial Community:

It is with tremendous sadness that we learned of Frank Samuel’s passing on October 20, 2014. Among his many accomplishments and titles, he was the first and active president of VentureOhio and undeniably essential in its founding. He served as colleague, mentor, and friend to all of us.

Frank’s unique talents brought together Ohio’s diverse venture community into the first statewide organization dedicated to advocating for entrepreneurial businesses and sources of capital, building the association to over 90 members in just its first year of operations. Under his guidance the group advocated for public policy initiatives and conducted two important surveys; a capital needs survey and an investment activity survey, both of which were the first of their kind for Ohio.

Frank was a champion of Ohio’s growing entrepreneurial ecosystem and his tireless and unyielding commitment to the entrepreneurial community will leave a lasting legacy.

He respected those who helped create the venture capital industry in Ohio and honored that heritage by establishing the VentureOhio David T. Morgenthaler Lifetime Achievement Award and recognition for those who are creating and supporting Ohio’s start-up companies.

At the time of Frank’s passing, he was working with VentureOhio’s Board of Directors on a succession plan for the organization’s day-to-day leadership. That plan will now be completed and announced to the membership in the coming months.

The Board of Directors is committed to continuing and building on the momentum created by Frank in VentureOhio’s first year, including the highly successful VentureDinner attended by over 250 in September and the recently published 2013 VentureReport, and will seek to honor Frank and his efforts as it carries VentureOhio’s important mission forward.

On behalf of Ohio’s entrepreneurial community, VentureOhio expresses our deepest condolences to Frank’s wife, Jacqueline, and the entire Samuel family. Frank’s talents and energy will be deeply missed by everyone at VentureOhio and in the entrepreneurial community.

John McIlwraith, VentureOhio Chairman

Two great events in Northeast Ohio!

Posted by BioOhio on Oct. 10, 2014

BioOhio is excited to host two events in Northern Ohio this Thursday! We hope to see everyone from the bioscience community represented at one or both of these excellent functions on October 16th!

BioOhio Annual Conference Road Show

BioOhio Regulatory Forum

The Annual Conference focuses on innovation and growth in Ohio’s bioscience community, and the Regulatory Forum features presentations by FDA and industry experts, as well as panel discussions for you to ask the experts your unanswered regulatory questions.

Both events offer content from dynamic speakers, excellent networking, and will bring Ohio’s bioscience community together to explore new opportunities and discoveries in research, innovation, tech licensing, financing, business development, partnerships, workforce & education, regulatory, advocacy and membership benefits.

The location is The Bertram Inn & Conference Center in Aurora. This beautiful venue will allow you to escape from routine surroundings for a day and focus on the root of your bioscience pathway, career, goals and challenges.

Visit the event pages on our website to view agenda and registration details: Annual Conference / Regulatory Forum

 

Higher Risk, Higher Reward Innovations are the Future

Posted by BioOhio on Oct. 06, 2014

AC2014-Andrew-CothrelBioOhio is glad to introduce a new contributor to micrOHscope, Andrew Cothrel, CEO of BioOhio member company NovoSource. Andrew has had a long career as a medtech/biotech executive, advisor, and consultant, covering diagnostics & patient monitoring, life science research tools, and medical devices including orthopedics, cardiovascular, and surgical tools.

Thanks again to BioOhio for inviting me to be part of its September 18th conference. I wanted to provide some follow-up to my comments during the panel discussion on innovation, because I received a number of questions after the panel adjourned that we ran out of time to answer.

In the panel, I spoke of how innovation is changing, and opportunities are moving in the venture model from reimbursement-driven incremental product innovation to business model innovation and step-change product innovation. To illustrate, I used some examples from orthopedics, although the comments apply to many other fields as well.

To clarify, I am definitely not saying that incremental innovation in orthopedics, even in areas as staid as total knees and total hips, is dead – far from it. What I wanted to communicate is that incremental innovation – whether it is an improved coating that better promotes bony ingrowth, or a design feature that makes future revisions easier, or whatever it may be – is no longer the province of the venture model. Those types of innovations will come exclusively from the large, established players, because the amount of clinical improvement those incremental innovations create does not justify the costs and risks (relative to the reward) associated with pursuing them in a venture model.

Where the venture model will turn (has turned) in orthopedics is to the higher risk, higher reward innovations that have the potential to make step-change improvements in patient outcomes. Whether it is in biologics, nano-materials, or other areas of innovation, this is the future of the venture model in orthopedics. To be blunt, the days of cranking up yet another set of (more or less functionally equivalent) designs for a spine product line (or knee, or hip…), pretending that is product innovation, and raising private capital around it are over.

What is really ripe for innovation is the non-product side of the orthopedic business. Risk sharing, pricing models, asset ownership, “repless” models, servicing of instruments, and more are beginning to experience disruptive approaches that can come from either venture-backed models or existing industry players. We are seeing signs that this is increasingly being recognized in the industry, and being part of this change as it plays out will be an exciting journey.

I hope that helps to address many of the questions I did not have time to address on the 18th. If anyone has additional questions on this topic, I can be contacted at acothrel@novosource.net or a.cothrel@bluemarblemedical.com.

And while I’m at it, I hope to see everyone at BioOhio’s Central Ohio Annual Conference Road Show on November 12th. I’ll be on a panel for a different topic this time – focusing on successful business strategies, including David Blauer of Bjond Health, Joseph Gardner of Aerpio Therapeutics and Neill Lane of Stirling Ultracold.

BIO Washington Update, October 2014

Posted by BioOhio on Oct. 06, 2014

CSBA BIO and Republic Consulting

October 6, 2014

Legislators worked efficiently to address key legislation in September before adjourning for the mid-term elections. Congress approved a continuing resolution (CR) to extend federal funding of government agencies through December 11, 2014. Both the Administration and Congress moved forward on some tax and transportation issues, while continuing to defer action on the expired tax extenders and a possible executive order on immigration. Much of the month was defined by events transpiring outside of the U.S., including the deteriorating situation in Iraq and Syria and the Ebola outbreak in Western Africa. Many of these issues will require additional consideration when Congress returns in November for the Lame Duck session.

ISSUE – GOVERNMENT FUNDING

With the clock ticking down, Congress agreed to extend funding for the federal government at existing funding levels before leaving for election season. The government had been operating on funding from a previous CR that was set to expire at the end of Fiscal Year 2014 (FY14) on September 30, 2014. The new CR will fund the government through December 11, 2014.

(more…)

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

43North competition awards OSU student’s Genetesis $260K and People’s Choice award | Columbus Business First, October 31, 2014

New study shows combining GanedenBC30 with prebiotics provides digestive health benefits | Ganeden, October 30, 2014

Charles River acquires ChanTest for up to $54M | GEN, October 30, 2014

Ashland Specialty Ingredients launches web-based film-coatings troubleshooting tool and new pharmaceutical excipients website | PR Web, October 30, 2014

IBM and Cleveland Clinic use Watson to advance genomic research for cancer care pilot | PR Newswire, October 29, 2014

Cleveland Clinic announces Top Ten medical innovations for 2015, mobile stroke unit and Dengue vaccine top list (video) | Cleveland.com, October 29, 2014

Ampersand Capital Partners exits ChanTest investment with sale to Charles River Laboratories | PR Newswire, October 29, 2014

Camargo Pharmaceutical Services meets growing client needs with appointment of industry leader Steven Castillo as Vice President Of Drug Development | BioSpace, October 29, 2014

Scientific breakthrough at Cincinnati Children’s Hospital Medical Center could help battle cancer, ulcers | Cincinnati Business Courier, October 29, 2014

Devicor Medical Products of Sharonville, Ohio acquired by Danaher Corporation’s Leica Biosystems | Cincinnati.com, October 28, 2014

GTCR announces sale of Devicor Medical Products to Danaher Corporation’s Leica Biosystems | Business Wire, October 28, 2014

Researchers at Cincinnati Children’s Hospital Medical Center studying how to create replacement organs for people who need transplants | Cincinnati Business Courier, October 28, 2014

Juventas Therapeutics strengthens management team with new senior vice president of finance and operations, Troy Ignelzi | PR Newswire, October 28, 2014

Enable Injections signs strategic development agreement with CSL Behring to market novel drug delivery device | Philadelphia Business Journal, October 28, 2014

Ohio’s 2014 Bioproduct World Conference names Magic Dirt of Little Rock, Arkansas the Bioproduct Innovation of the Year | Wisconsin State Farmer, October 28, 2014

Ohio Soybean Council Foundation offers $36,000 in scholarships, majors include biotechnology | Ohio Soybean Council Foundation, October 28, 2014

Danaher’s Leica Biosystems division agrees to buy Devicor Medical Products, a developer of breast biopsy products | MASS Device, October 28, 2014

University Hospitals selects GenomOncology’s GO Clinical Workbench to launch their first NGS-based cancer diagnostic test | PR Newswire, October 27, 2014

INC Research of Raleigh, NC and the former Kendle location in Cincinnati, OH, plans IPO of up to $156M | Triangle Business Journal, October 27, 2014

NASA Glenn Research Center’s new office building is an example of continued commitment to Brook Park | Cleveland.com, October 27, 2014